Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ER opioid overdose study pulled before it began

NCT ID NCT03968237

Disease control Sponsor: Nassima Ait-Daoud Tiouririne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study aimed to help people who had an opioid overdose by starting them on buprenorphine/naloxone in the emergency room and then connecting them to an addiction clinic. The goal was to reduce repeat overdoses and improve treatment engagement. However, the study was withdrawn before enrolling any participants, so no data was collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
buprenorphine/naloxone
What this could lead to
If successful, this approach could help people recover from opioid overdose by starting medication in the ER and connecting them to ongoing addiction care.
What could go wrong
The study was withdrawn before enrolling anyone, so no results are available. It was a small pilot, and even if tested, success in linking patients to treatment is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Started

Aug 2019

Finished

Dec 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients from Emergency Room Department

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Person can read, write, and speak in English. * Presenting to the University of Virginia ED with opioid overdose and administration of naloxone either by EMS or in the ED. * Experiencing some withdrawal symptoms (COWS score of 12 or higher) or experiencing 3 of the following symptoms: tremor/twitching, irritability, joint or bone aches, bad chills or sweating, goose bumps * Express an interest in receiving a buprenorphine/naloxone induction with the goal to continue the same treatment outpatient Exclusion Criteria: * Non-opioid substance overdose or overdose that does not respond to naloxone * Patients requiring admission secondary to medical or psychiatric complications * Patients on prescribed methadone * Women who are pregnant; This medication may precipitate opioid withdrawal in pregnant patients with opioid use disorder. Withdrawal can harm the placenta function, preterm labor, fetal convulsions (seizures), stunted fetal growth and fetal death during pregnancy. * Mothers who are breastfeeding * Persons under the age of 18 * Persons not able to attend follow-up clinic visits * Persons not able to consent * Known allergy or sensitivity to buprenorphine

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Opioid overdose are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute opioid poisoning opiate dependence Opiate Overdose

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Opioid overdose

Contacts and locations

Locations

  • UVA Center for Leading Edge Addiction Research

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.